Emerging Biohybrids of Aptamer-Based Nano-Biosensing Technologies for Effective Early Cancer Detection
- PMID: 38775897
- DOI: 10.1007/s40291-024-00717-x
Emerging Biohybrids of Aptamer-Based Nano-Biosensing Technologies for Effective Early Cancer Detection
Abstract
Cancer is a leading global cause of mortality, which underscores the imperative of early detection for improved patient outcomes. Biorecognition molecules, especially aptamers, have emerged as highly effective tools for early and accurate cancer cell identification. Aptamers, with superior versatility in synthesis and modification, offer enhanced binding specificity and stability compared with conventional antibodies. Hence, this article reviews diagnostic strategies employing aptamer-based biohybrid nano-biosensing technologies, focusing on their utility in detecting cancer biomarkers and abnormal cells. Recent developments include the synthesis of nano-aptamers using diverse nanomaterials, such as metallic nanoparticles, metal oxide nanoparticles, carbon-derived substances, and biohybrid nanostructures. The integration of these nanomaterials with aptamers significantly enhances sensitivity and specificity, promising innovative and efficient approaches for cancer diagnosis. This convergence of nanotechnology with aptamer research holds the potential to revolutionize cancer treatment through rapid, accurate, and non-invasive diagnostic methods.
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
References
-
- Blackley D, Behringer B, Zheng S. Cancer mortality rates in Appalachia: descriptive epidemiology and an approach to explaining differences in outcomes. J Commun Health. 2012;37:804–13. - DOI
-
- Alberini A, Rheinberger CM, Ščasný M. All cancers are not created equal: how do survival prospects affect the willingness to pay to avoid cancer? J Benefit Cost Anal. 2023;14(1):93–113. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
